Patrick Stiff
Overview
Explore the profile of Patrick Stiff including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
52
Citations
3257
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Norton J, Stiff P
Discov Oncol
. 2025 Jan;
16(1):49.
PMID: 39812904
CAR-T cell therapies have risen to prominence over the last decade, and their indications are increasing with several products approved as early as second line in Large B Cell non-Hodgkin...
2.
Gyurkocza B, Nath R, Seropian S, Choe H, Litzow M, Abboud C, et al.
J Clin Oncol
. 2024 Sep;
43(2):201-213.
PMID: 39298738
Purpose: Older patients with relapsed or refractory AML (RR AML) have dismal prognoses without allogeneic hematopoietic cell transplantation (alloHCT). SIERRA compared a targeted pretransplant regimen involving the anti-CD45 radioconjugate I-apamistamab...
3.
Oluwole O, Forcade E, Munoz J, de Guibert S, Vose J, Bartlett N, et al.
Bone Marrow Transplant
. 2024 Jan;
59(3):366-372.
PMID: 38177222
ZUMA-1 safety management cohort 6 investigated the impact of prophylactic corticosteroids and earlier corticosteroids and/or tocilizumab on the incidence and severity of cytokine release syndrome (CRS) and neurologic events (NEs)...
4.
Hagen P, Norton J, Tsai S, Campo L, Lee M, Gomez K, et al.
Br J Haematol
. 2024 Jan;
204(4):1422-1428.
PMID: 38176404
The standard of care for fit, newly diagnosed multiple myeloma patients includes induction therapy followed by consolidative high-dose chemotherapy with melphalan and autologous stem cell transplant (AHSCT). Intensified preparative regimens,...
5.
Mumby P, Adams W, Smith S, Rao M, Stiff P
Transplant Cell Ther
. 2023 Dec;
30(3):320.e1-320.e11.
PMID: 38147899
Depression and decreased quality of life (QoL) develop in approximately 30% of nondepressed hematopoietic stem cell transplantation (HSCT) recipients early after transplantation. To potentially prevent this complication, we conducted a...
6.
Kalinina O, Minter L, Sperling A, Hollinger M, Le P, Osborne B, et al.
Transplant Cell Ther
. 2023 Nov;
30(1):79.e1-79.e10.
PMID: 37924979
Graft-versus-host disease (GVHD) is a primary and often lethal complication of allogenic hematopoietic stem cell transplantation (HSCT). Prophylactic regimens for GVHD are given as standard pretransplantation therapy; however, up to...
7.
Szabolcs P, Mazor R, Yackoubov D, Levy S, Stiff P, Rezvani A, et al.
Transplant Cell Ther
. 2023 Apr;
29(8):517.e1-517.e12.
PMID: 37120136
Allogeneic hematopoietic cell transplantation (HCT) is a potentially curative treatment for hematologic malignancies and nonmalignant disorders. Rapid immune reconstitution (IR) following allogeneic HCT has been shown to be associated with...
8.
Crees Z, Rettig M, Jayasinghe R, Stockerl-Goldstein K, Larson S, Arpad I, et al.
Nat Med
. 2023 Apr;
29(4):869-879.
PMID: 37069359
Autologous hematopoietic stem cell transplantation (ASCT) improves survival in multiple myeloma (MM). However, many individuals are unable to collect optimal CD34 hematopoietic stem and progenitor cell (HSPC) numbers with granulocyte...
9.
Chakraborty R, Yi J, Rybicki L, Preussler J, Deol A, Loren A, et al.
Transplant Cell Ther
. 2023 Mar;
29(6):388.e1-388.e6.
PMID: 36870388
The overall survival in patients with transplantation-eligible multiple myeloma has tripled over the past 2 decades, leading to a growing population of myeloma survivors. However, there is a paucity of...
10.
Neelapu S, Jacobson C, Ghobadi A, Miklos D, Lekakis L, Oluwole O, et al.
Blood
. 2023 Feb;
141(19):2307-2315.
PMID: 36821768
In phase 2 of ZUMA-1, a single-arm, multicenter, registrational trial, axicabtagene ciloleucel (axi-cel) autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy demonstrated durable responses at 2 years in patients with...